Lee Ainslie United Therapeutics Corp Transaction History

Maverick Capital LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$184.32 - $216.08 $803,819 - $942,324	-4,361 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$179.86 - $214.88 $718,001 - $857,800	-3,992 Reduced 47.79%	4,361 $805,000
Q2 2021 Aug 16, 2021	BUY	$170.47 - $211.93 $143,024 - $177,809	839 Added 11.17%	8,353 $1.5 Million
Q1 2021 May 17, 2021	BUY	$153.94 - $174.85 $1.16 Million - $1.31 Million	7,514 New	7,514 $1.26 Million
Q1 2020 May 15, 2020	SELL	$79.39 - $115.35 $1.17 Million - $1.7 Million	-14,781 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$78.31 - $95.34 $158,107 - $192,491	2,019 Added 15.82%	14,781 $1.3 Million
Q3 2019 Nov 14, 2019	BUY	$74.85 - $85.99 $955,235 - $1.1 Million	12,762 New	12,762 $1.02 Million

692

60.6M

194K

298K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $15.8B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.